WALTHAM, Mass., April 19, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its first quarter 2017 financial results will be released on Tuesday, May 2, 2017 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: (877) 412-6083
International Dial-in Number: (702) 495-1202
Conference ID: 3903846
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 3903846
A telephone replay will be available from approximately 11:00 a.m. ET on May 2, 2017 through midnight on May 9, 2017.
The webcast with slides will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will be archived on the website for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of women’s and maternal health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638


Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 



